SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen rec...

by Carla L. Alves, Daniel Elias, Maria B. Lyng, Martin Bak, Henrik J. Ditzel
Published 2018-06-01

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

by Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Published 2021-09-01

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

by Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Published 2021-08-01

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

by Kamila Kaminska, Nina Akrap, Johan Staaf, Carla L. Alves, Anna Ehinger, Anna Ebbesson, Ingrid Hedenfalk, Lukas Beumers, Srinivas Veerla, Katja Harbst, Sidse Ehmsen, Signe Borgquist, Åke Borg, Alejandro Pérez-Fidalgo, Henrik J. Ditzel, Ana Bosch, Gabriella Honeth
Published 2021-02-01

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

by Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Published 2021-01-01